The FDA has confirmed the picks to head most of the new offices in the restructured drug review organization, with one notable exception. The choice for the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine is still pending, while one candidate – Hylton Joffe – will be serving as acting OND deputy director.
The next phase of the US Food and Drug Administration’s roll-out of a new structure for its drug review operations will take place in mid-January.
Phase 3 of the four-stage roll-out had been tentatively scheduled to take effect 2 December. However, the FDA announced 25...